JFG Wealth Management LLC Makes New Investment in Illumina, Inc. (NASDAQ:ILMN)

JFG Wealth Management LLC purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,000 shares of the life sciences company’s stock, valued at approximately $278,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Illumina by 15.0% during the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock valued at $2,466,614,000 after purchasing an additional 2,336,935 shares in the last quarter. Barclays PLC boosted its position in Illumina by 120.0% during the 3rd quarter. Barclays PLC now owns 1,768,355 shares of the life sciences company’s stock worth $242,758,000 after buying an additional 964,709 shares during the period. abrdn plc boosted its position in Illumina by 764.9% during the 4th quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock worth $47,206,000 after buying an additional 299,827 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Illumina by 245.7% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 417,876 shares of the life sciences company’s stock valued at $57,366,000 after acquiring an additional 296,990 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Illumina by 6.6% during the third quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock valued at $500,926,000 after acquiring an additional 225,074 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ILMN shares. Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Illumina in a research note on Wednesday, April 10th. TD Cowen lowered Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target on the stock. in a research report on Thursday, January 4th. Royal Bank of Canada restated an “outperform” rating and set a $253.00 price objective on shares of Illumina in a research report on Tuesday, April 9th. StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Finally, HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $167.70.

Illumina Stock Down 0.5 %

Shares of NASDAQ:ILMN traded down $0.57 during midday trading on Thursday, hitting $124.11. 386,691 shares of the company’s stock were exchanged, compared to its average volume of 1,682,525. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $213.91. The company has a market cap of $19.77 billion, a PE ratio of -16.99 and a beta of 1.20. The stock has a 50 day moving average price of $130.57 and a 200-day moving average price of $127.14.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.14 earnings per share. On average, sell-side analysts anticipate that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Jacob Thaysen bought 7,330 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were purchased at an average price of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now directly owns 14,861 shares in the company, valued at $2,010,544.69. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.17% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.